Legend Biotech (LEGN) Cash from Investing Activities (2019 - 2025)

Legend Biotech has reported Cash from Investing Activities for 7 years, with the latest figure at $638.5 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Investing Activities rose 826.39% year-over-year to $638.5 million; the trailing twelve-month figure through Dec 2025 stood at $709.6 million (up 183.42% YoY), and the FY2025 full-year result was $709.6 million, up 183.42% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at $638.5 million, up from -$20.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $638.5 million in Q4 2025, with the low at -$695.6 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$35.8 million across 5 years, with a median of -$83.1 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 4807.27% — and 2025, when it jumped 826.39%.
• Legend Biotech's Cash from Investing Activities stood at -$195.0 million in 2021, then jumped by 59.82% to -$78.3 million in 2022, then soared by 620.15% to $407.5 million in 2023, then slumped by 121.57% to -$87.9 million in 2024, then jumped by 826.39% to $638.5 million in 2025.
• The last three Cash from Investing Activities figures came in at $638.5 million (Q4 2025), -$20.0 million (Q3 2025), and -$165.5 million (Q2 2025), per Business Quant data.